Fig. 4

Flow cytometric analysis of T cell populations in the spleen and MLN. Cells were gated based on FSC–SSC properties and the Fluorescence-minus-one (FMO) technique. a, b Percentage of activated Th2 cells (T1/ST2+ CD69+ of CD4+) in spleen. c, d Percentage of activated Th1 cells (CXCR3+ CD69+ of CD4+) in spleen. e, f Percentage of activated CD4+ cells (CD4+ CD69+ of CD3+) in spleen. g, h Percentage of Tregs (CD25+ FoxP3+ of CD4+) in spleen. i Percentage of Tregs (CD25+ FoxP3+ of CD4+) in MLN of CMA animals. j Percentage of activated CD4+ cells (CD4+ CD69+ of CD3+) in MLN of CMA animals. k Percentage of activated Th2 cells (T1/ST2+ CD69+ of CD4+) in MLN of CMA animals. l Percentage of activated Th1 cells (CXCR3+ CD69+ of CD4+) in MLN of CMA animals. All data are represented as mean ± SEM n = 6/8 mice/group. Statistical analysis was performed using one-way ANOVA and Dunnett’s post hoc test for multiple comparisons. ^#P < 0.05; ^##P < 0.01; ^###P < 0.001; ^####P < 0.0001 compared to sham control control. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001 compared to whey- or PE-sensitized control. PE, peanut extract; OIT, oral immunotherapy; SCIT, subcutaneous immunotherapy; IT, immunotherapy